Monica M. Rivera Franco

Monica M. Rivera Franco

Auto-generated profile, based on publicly available information

Monica M. Rivera Franco

Stem Cell Transplantation Program, Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
MRMonica M Rivera-Franco
Monica M Rivera-Franco
ELEucario Leon-Rodriguez
Eucario Leon-Rodriguez
Breast cancer is the most common cancer in women in both developed and developing countries and the second most common cancer in the world. Developing countries are increasingly adopting a Western lifestyle, such as changes in diet and delayed first childbirth, lower parity, and shorter periods of breastfeeding, which are important determinants of a higher incidence of breast cancer among those regions. Low- and middle-income countries (LMICs) represent most of the countries with the highest mortality rates, ranging from 40% to 60%. Furthermore, developing countries account for scarce survival data, and the few data available coincide with the observed incidence and mortality differences. Five-year survival rates for breast cancer are much worse for LMICs countries such as Brazil, India, and Algeria in comparison with the United States and Sweden. Paucity of early detection programs explain these poor survival rates, which results in a high proportion of women presenting with late-stage disease, along with lack of adequate diagnosis and treatment facilities. Emphasis is urgently needed on health education, to promote early diagnosis of breast cancer, highlighting the importance of creating more public facilities that provide treatment, which are key components for the improvement in breast cancer care in developing countries.

27 October 2019 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
MRMonica M. Rivera-Franco
Monica M. Rivera-Franco
ELEucario Leon-Rodriguez
Eucario Leon-Rodriguez
JTJosé J. Torres-Ruiz
José J. Torres-Ruiz
DGDiana Gómez-Martín
Diana Gómez-Martín
EAEduardo Angles-Cano
Eduardo Angles-Cano
MSMaría de la Luz Sevilla-González
María de la Luz Sevilla-González

30 October 2017 in Nutrition and Cancer
Verified
Journal Article
Closed access
DCDana A. Pérez Camargo
Dana A. Pérez Camargo
SPSilvia R. Allende Pérez
Silvia R. Allende Pérez
EAEmma Verastegui Avilés
Emma Verastegui Avilés
MFMónica M. Rivera Franco
Mónica M. Rivera Franco
AGAbelardo Meneses García
Abelardo Meneses García
VCVíctor I. Urbalejo Ceniceros
Víctor I. Urbalejo Ceniceros
Sarcopenia has been evaluated as a separate condition in cancer patients and as an important indicator of adverse outcomes. Muscle mass and phase angle are usually quantified by bioelectrical impedance analysis, due to its lower cost, and availability. The aim of this study was to assess the impact of sarcopenia, phase angle, and other characteristics on overall survival (OS) in palliative cancer patients at the National Cancer Institute of Mexico. We enrolled 628 patients (female, 59%). The most frequent disease was gastric cancer (39.5%). Kaplan–Meier analysis showed a significant survival disadvantage for patients with sarcopenia compared to patients without sarcopenia (p = 0.02). Sarcopenia univariably predicted OS [HR 1.4 (95% CI, 1.1–1.8), p = 0.001], but was not significant in multivariable Cox-regression analysis (p = 0.08). Significant predictors for sarcopenia in multivariable Cox-regression analysis were sex, age, body mass index, phase angle, clinical symptoms, and Karnofsky. Our results corroborate the reliability of sarcopenia and phase angle in Mexican population, showing that the measurement of these parameters might also be useful in early-stage cancer patients as prognostic markers.

29 March 2017 in Nutrition and Cancer
Verified
Journal Article
Closed access
DCDana A. Pérez Camargo
Dana A. Pérez Camargo
SPSilvia R. Allende Pérez
Silvia R. Allende Pérez
MFMónica M. Rivera Franco
Mónica M. Rivera Franco
NLNelson E. Álvarez Licona
Nelson E. Álvarez Licona
VCVíctor I. Urbalejo Ceniceros
Víctor I. Urbalejo Ceniceros
LBLilian E. Figueroa Baldenegro
Lilian E. Figueroa Baldenegro
Patients with advanced cancer often experience symptoms of disease and treatment that contribute to distress such as weight loss, which is present in up to 85% of cancer patients. Palliative care in these patients focuses on care aimed at improving quality of life. Phase angle (PA) is obtained by bioelectric impedance analysis (BIA) and is associated with cellular function. It is considered a reliable marker of malnutrition. A low PA may suggest deterioration of the cell membrane, which in palliative patients may result in a short-term survival. The aim of this study was to associate PA and survival in palliative patients of the National Cancer Institute of Mexico. We included 452 patients (women, 56.4%); the average PA was 4.0°. The most frequent disease was gastric cancer (39.2%). Mean body mass index (BMI) was 22.84. The average survival of patients with PA ≤ 4° was 86 days, while in the group with PA > 4°, it was 163 days (P > 0.0001). PA showed significant positive correlation with survival time and BMI. Our results corroborate the reliability of PA in Mexican population, as an indicator of survival in palliative care patients compared to the reported literature in other countries.

25 April 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ELEucario Leon-Rodriguez
Eucario Leon-Rodriguez
CMC. Molina-Calzada
C. Molina-Calzada
MRM. M. Rivera-Franco
M. M. Rivera-Franco
ACA. Campos-Castro
A. Campos-Castro

14 June 2017 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MRMonica M. Rivera-Franco
Monica M. Rivera-Franco
ELEucario Leon-Rodriguez
Eucario Leon-Rodriguez
HCHaydee L. Castro-Saldaña
Haydee L. Castro-Saldaña